Article
Biochemistry & Molecular Biology
Khrystany T. Isebia, Martijn P. Lolkema, Guido Jenster, Ronald de Wit, John W. M. Martens, Job van Riet
Summary: This study found that in metastatic castration-resistant prostate cancer, in addition to AR-V7, AR45 and AR-V3 were also commonly seen AR splice variants. The presence of any AR-Vs may be associated with higher AR expression. These AR-Vs could potentially serve as predictive and prognostic biomarkers in metastatic castration-resistant prostate cancer, similar or complementary to AR-V7.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Kim N. Chi, Dana Rathkopf, Matthew R. Smith, Eleni Efstathiou, Gerhardt Attard, David Olmos, Ji Youl Lee, Eric J. Small, Andrea J. Pereira De Santana Gomes, Guilhem Roubaud, Marniza Saad, Bogdan Zurawski, Valerii Sakalo, Gary E. Mason, Peter Francis, George Wang Ms, Daphne Wu, Brooke Diorio, Angela Lopez-Gitlitz, Shahneen Sandhu
Summary: This study investigated the efficacy of niraparib in combination with abiraterone acetate plus prednisone in patients with mCRPC and HRR gene alterations. The results showed that the combination therapy significantly prolonged radiographic progression-free survival compared to abiraterone acetate plus prednisone alone. The treatment was well tolerated with manageable adverse events.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Edoardo Francini, Fang-Shu Ou, Justin Rhoades, Eric G. Wolfe, Edward P. O'Connor, Gavin Ha, Gregory Gydush, Kaitlin M. Kelleher, Rupal S. Bhatt, Steven P. Balk, Christopher J. Sweeney, Viktor A. Adalsteinsson, Mary-Ellen Taplin, Atish D. Choudhury
Summary: This study aimed to evaluate the association between ABC transporter gene ABCB1 amplification and primary resistance to docetaxel or cabazitaxel in mCRPC patients using sparse whole genome sequencing, but no significant correlation was found. Future studies with larger sample sizes including ABCB1 amplification and a suite of putative biomarkers are needed to draw definitive conclusions.
Article
Oncology
Matti Annala, Sinja Taavitsainen, Daniel J. Khalaf, Gillian Vandekerkhove, Kevin Beja, Joonatan Sipola, Evan W. Warner, Cameron Herberts, Amanda Wong, Simon Fu, Daygen L. Finch, Conrad D. Oja, Joanna Vergidis, Muhammad Zulfiqar, Bernhard J. Eigl, Christian K. Kollmansberger, Matti Nykter, Martin E. Gleave, Kim N. Chi, Alexander W. Wyatt
Summary: In patients with mCRPC, sequential AR signaling inhibitor treatment leads to continuous evolution of the AR genotype, driving acquired resistance mainly through changes in the AR gene.
CLINICAL CANCER RESEARCH
(2021)
Review
Cell Biology
Vincenza Conteduca, Alessandra Mosca, Nicole Brighi, Ugo de Giorgi, Pasquale Rescigno
Summary: Prostate cancer is a common cancer in men and patients may develop metastatic disease after radical treatments. Prognostic biomarkers are urgently needed to define patients' risk of cancer-related death.
Article
Urology & Nephrology
Heidi Fettke, Edmond M. Kwan, Patricia Bukczynska, Nicole Ng, Tu Nguyen-Dumont, Melissa C. Southey, Ian D. Davis, Andrew Mant, Phillip Parente, Carmel Pezaro, Christine Hauser, Arun A. Azad
Summary: Measuring changes in total cell-free DNA levels in plasma can help predict how patients with metastatic prostate cancer will respond to different treatments. Higher levels or changes in cfDNA concentration may be associated with worse treatment outcomes, but in some cases, an increase in total cfDNA levels may correlate with better efficacy.
EUROPEAN UROLOGY FOCUS
(2021)
Article
Urology & Nephrology
Liancheng Fan, Xiaochen Fei, Yinjie Zhu, Jiahua Pan, Jianjun Sha, Chenfei Chi, Yiming Gong, Xinxing Du, Lixin Zhou, Baijun Dong, Wei Xue
Summary: This study investigated the genomic profiles of Chinese patients with different stages of prostate cancer using germline and circulating tumor DNA sequencing. The results showed a similar frequency of deleterious germline alterations between patients with castration sensitive prostate cancer and metastatic castration resistant prostate cancer. Circulating tumor DNA sequencing may guide clinical treatment for metastatic prostate cancer.
JOURNAL OF UROLOGY
(2021)
Article
Biochemistry & Molecular Biology
Guangbao Wang, Xiaojing Chen, Nan Wang, Yunbei Xiao, Sheng Shu, Ali Mohammed Mohammed Alsayed, Lu Liu, Yue Ma, Peng Liu, Qianwen Zhang, Xiangjuan Chen, Zhiguo Liu, Xiaohui Zheng
Summary: A series of sanjuanolide derivatives were designed, synthesized and evaluated as potential anti-CRPC agents, with most compounds showing excellent selectivity for CRPC cells. The representative compound S07 selectively induced CRPC cell death by triggering intense DNA damage and DNA damage response.
BIOORGANIC CHEMISTRY
(2021)
Article
Biochemistry & Molecular Biology
Maria Concetta Cursano, Emilio Francesco Giunta, Emanuela Scarpi, Chiara Casadei, Alessandra Virga, Paola Ulivi, Sara Bleve, Nicole Brighi, Giorgia Ravaglia, Francesco Pantano, Vincenza Conteduca, Daniele Santini, Ugo De Giorgi
Summary: This study evaluated the prevalence of DNA damage repair (DDR) gene mutations in castration-resistant prostate cancer (CRPC) patients and their impact on clinical outcomes related to bone metastases. The results showed that DDR mutations were associated with larger bone metastases volume, but did not affect skeletal-related events incidence and time to onset.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Endocrinology & Metabolism
Heidi Fettke, Edmond M. Kwan, Patricia Bukczynska, Jason A. Steen, Maria Docanto, Nicole Ng, Phillip Parente, Andrew Mant, Siavash Foroughi, Carmel Pezaro, Christine Hauser, Tu Nguyen-Dumont, Melissa C. Southey, Arun A. Azad
Summary: The study found that variations in NCOA2 can impact patients' survival rates and treatment responses in metastatic castration-resistant prostate cancer (mCRPC), especially in relation to variations in the AR pathway. This helps to better understand treatment strategies and prognosis for mCRPC, and further research is needed to determine if NCOA2 variations could serve as markers of resistance to AR pathway inhibitors.
Article
Oncology
Maha Hussain, Claire Corcoran, Caroline Sibilla, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Joaquin Mateo, David Olmos, Niven Mehra, Michael P. Kolinsky, Guilhem Roubaud, Mustafa Ozguroglu, Nobuaki Matsubara, Craig Gedye, Young Deuk Choi, Charles Padua, Alexander Kohlmann, Robert Huisden, Julia A. Elvin, Jinyu Kang, Carrie A. Adelman, Allison Allen, Christian Poehlein, Johann de Bono
Summary: Successful implementation of genomic testing in clinical practice is critical for identifying men with mCRPC who are eligible for olaparib and future targeted therapies. This study used an investigational clinical trial assay based on the FoundationOneCDx tissue test to prospectively identify patients with homologous recombination repair gene alterations. Evaluation of NGS tissue test outcomes against preanalytic parameters was performed to identify key factors that influence the results.
CLINICAL CANCER RESEARCH
(2022)
Review
Pathology
Vincenza Conteduca, Nicole Brighi, Donato Conteduca, Sara Bleve, Caterina Gianni, Giuseppe Schepisi, Maria Laura Iaia, Giorgia Gurioli, Cristian Lolli, Ugo De Giorgi
Summary: Cell-free DNA holds significant clinical value in metastatic CRPC, providing a comprehensive molecular landscape.
Evaluation of circulating tumor DNA fraction serves as a reliable biomarker in mCRPC, predicting clinical outcomes and monitoring disease progression.
Various methods are being utilized to study genomics in cell-free DNA, aiming to enhance clinical management of mCRPC patients.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
(2021)
Article
Oncology
Bobby C. Liaw, Che-Kai Tsao, Sonia Seng, Tomi Jun, Yixuan Gong, Matthew D. Galsky, William K. Oh
Summary: This study evaluated the feasibility and usefulness of blood-based biomarkers to identify platinum-sensitive mCRPC. Although some biomarkers were assessed, none were significantly associated with response to satraplatin.
Article
Biochemistry & Molecular Biology
Maria J. Orea, Javier C. Angulo, Ana Gonzalez-Corpas, David Echegaray, Marcos Marva, Maria V. T. Lobo, Begona Colas, Santiago Ropero
Summary: The development of castration-resistant prostate cancer (CRPC) is a major concern in high-risk patients after treatment for locally advanced or metastatic prostate cancer. Androgen receptor (AR) is implicated in CRPC development through its interaction with epigenetic modifier genes, highlighting the significance of epigenetic modifications. Our study reveals the epigenetic silencing of claudin-3 (CLDN3) in AR-positive CRPC cells, which is associated with DNA methylation, histone acetylation loss, and H3K27 methylation. CLDN3 expression can be restored by combined treatment with epigenetic modulators. Additionally, decreased CLDN3 expression is observed in CRPC patient samples, particularly in patients with high Gleason scores and locally advanced tumors. CLDN3 loss is also linked to worse disease-free survival and time to clinical progression, suggesting its potential as a molecular marker for prognosis and distinguishing aggressive from indolent prostate tumors.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Karim Fizazi, Arun A. Azad, Nobuaki Matsubara, Joan Carles, Andre P. Fay, Ugo De Giorgi, Jae Young Joung, Peter C. C. Fong, Eric Voog, Robert J. Jones, Neal D. Shore, Curtis Dunshee, Stefanie Zschaebitz, Jan Oldenburg, Dingwei Ye, Xun Lin, Cynthia G. Healy, Nicola Di Santo, A. Douglas Laird, Fabian Zohren, Neeraj Agarwal
Summary: This study investigates the combination of the poly(ADP-ribose) polymerase inhibitor talazoparib with enzalutamide for the treatment of metastatic castration-resistant prostate cancer. The results show that the combination significantly improved radiographic progression-free survival in patients with specific gene alterations, suggesting it as a potential first-line treatment option.
Article
Andrology
Yuki Takai, Sei Naito, Hidenori Kanno, Atsushi Yamagishi, Mayu Yagi, Toshihiko Sakurai, Hayato Nishida, Takuya Yamanobe, Tomoyuki Kato, Norihiko Tsuchiya
Summary: Metabolic syndrome is a long-term complication of systemic chemotherapy for testicular germ cell tumor, causing changes in body composition with increased fat mass and decreased skeletal muscle mass. Fortunately, the skeletal muscle mass can recover within 12 months, but the fat mass continues to increase up to 24 months after chemotherapy.
ASIAN JOURNAL OF ANDROLOGY
(2022)
Article
Immunology
Hiroki Fukuhara, Hayato Nishida, Takaaki Nawano, Satoshi Takai, Takafui Narisawa, Hidenori Kanno, Mayu Yagi, Atsushi Yamagishi, Toshihiko Sakurai, Sei Naito, Tomoyuki Kato, Norihiko Tsuchiya
Summary: This study analyzed the changes in body composition of kidney transplant recipients before and 1, 3, and 5 years after transplantation. The results showed an increasing trend in abdominal adipose tissue mass at 1, 3, and 5 years post transplantation, while body mass index and skeletal muscle mass index did not differ significantly.
TRANSPLANTATION PROCEEDINGS
(2022)
Article
Immunology
Hayato Nishida, Takaaki Nawano, Hiroki Fukuhara, Satoshi Takai, Takafumi Narisawa, Hidenori Kanno, Mayu Yagi, Atsushi Yamagishi, Toshihiko Sakurai, Sei Naito, Tomoyuki Kato, Norihiko Tsuchiya
Summary: Kidney transplantation is a treatment option for renal failure caused by mitochondrial disease, but the prognosis for patients who undergo kidney transplantation for mitochondrial disease is unknown. This study evaluated the outcomes of kidney transplant recipients with mitochondrial disease.
TRANSPLANTATION PROCEEDINGS
(2022)
Article
Oncology
Masaki Shiota, Dai Takamatsu, Takahiro Kimura, Kojiro Tashiro, Yoshiyuki Matsui, Ryotaro Tomida, Ryoichi Saito, Masakazu Tsutsumi, Akira Yokomizo, Yoshiyuki Yamamoto, Kohei Edamura, Makito Miyake, Shuichi Morizane, Takayuki Yoshino, Akihiro Matsukawa, Shintaro Narita, Ryuji Matsumoto, Takashi Kasahara, Kohei Hashimoto, Hiroaki Matsumoto, Masashi Kato, Shusuke Akamatsu, Akira Joraku, Manabu Kato, Takahiro Yamaguchi, Toshihiro Saito, Tomoyuki Kaneko, Atsushi Takahashi, Takuma Kato, Shinichi Sakamoto, Hideki Enokida, Hidenori Kanno, Naoki Terada, Shigetaka Suekane, Naotaka Nishiyama, Masatoshi Eto, Hiroshi Kitamura
Summary: This study investigated the outcomes of various management strategies for patients with lymph node involvement (LNI) after radical prostatectomy (RP). The results showed that persistent prostate-specific antigen (PSA) was associated with inferior prognoses, and the addition of radiotherapy (RT) to androgen deprivation therapy (ADT) might improve survival.
Article
Biochemistry & Molecular Biology
Hidenori Kanno, Sei Naito, Yutaro Obara, Hiromi Ito, Osamu Ichiyanagi, Takafumi Narisawa, Tomoyuki Kato, Akira Nagaoka, Norihiko Tsuchiya
Summary: ERK5 has been found to be highly expressed in clear cell renal cell carcinoma (ccRCC) and is associated with high grade, high recurrence rate, and high cancer-specific survival. The expression of ERK5 is regulated by miR-143. Inhibition of ERK5 holds promise as a potential target for ccRCC treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Yu Miyazaki, Takayuki Goto, Xin Li, Kenji Nakayama, Kosuke Okasho, Masashi Takeda, Kei Mizuno, Hiroko Kimura, Masayuki Uegaki, Takayuki Sumiyoshi, Yuki Teramoto, Shusuke Akamatsu, Takashi Kobayashi, Osamu Ogawa, Takahiro Inoue
Summary: By analyzing the secreted proteins in culture supernatants, the study found that SLPI expression was higher in CRPC cell lines and was associated with lower PSA progression-free survival rate in localized prostate cancer patients. In addition, SLPI expression in CRPC patients was correlated with resistance to enzalutamide and radiographic progression of the disease.
Article
Oncology
Ken Saijo, Hiroo Imai, Hiromichi Katayama, Fumiyoshi Fujishima, Kenichi Nakamura, Yuki Kasahara, Kota Ouchi, Keigo Komine, Hidekazu Shirota, Masanobu Takahashi, Chikashi Ishioka
Summary: This is a case report on the treatment of a Japanese man with undifferentiated sarcoma using targeted therapy based on the BRAF V600E mutation. The patient initially responded well to the combination therapy but developed resistance after 6.5 months. Liquid comprehensive genomic profiling identified no actionable gene alterations other than BRAF V600E.
CASE REPORTS IN ONCOLOGY
(2022)
Article
Oncology
Takuya Nakagawa, Yoshihide Kawasaki, Satoko Sato, Hiromichi Katayama, Yohei Satake, Shuichi Shimada, Takuma Sato, Naoki Kawamorita, Shinichi Yamashita, Koji Mitsuzuka, Atsushi Kohyama, Masaharu Ishida, Hideo Ohtsuka, Michiaki Unno, Akihiro Ito
Summary: Deferred cytoreductive nephrectomy plays a significant role in the treatment of advanced renal cell carcinoma, with emphasis on the importance of image evaluation and pathological findings in guiding surgical and treatment choices.
CASE REPORTS IN ONCOLOGY
(2022)
Article
Oncology
Sofie H. Tolmeijer, Emmy Boerrigter, Takayuki Sumiyoshi, Edmond M. Kwan, Sarah W. S. Ng, Matti Annala, Grainne Donnellan, Cameron Herberts, Guillemette E. Benoist, Paul Hamberg, Diederik M. Somford, Inge M. van Oort, Jack A. Schalken, Niven Mehra, Nielka P. van Erp, Alexander W. Wyatt
Summary: This study aimed to investigate the relationship between changes in circulating tumor DNA (ctDNA) and clinical prognosis in patients with metastatic castration-resistant prostate cancer (mCRPC) during androgen receptor pathway inhibitor (ARPI) treatment. The results showed that a decrease in ctDNA fraction within 4 weeks was associated with longer duration of first-line ARPI treatment and improved survival, suggesting its potential to identify resistance early and guide treatment decisions.
CLINICAL CANCER RESEARCH
(2023)
Article
Medicine, General & Internal
Haruki Ito, Hiromitsu Negoro, Jin Kono, Naoki Hayata, Takayoshi Miura, Yumi Manabe, Yu Miyazaki, Mutsuki Mishina, Je Tae Woo, Naoki Sakane, Hiroshi Okuno
Summary: This study investigated the efficacy of Nobiletin and tangeretin for treating nocturia. The results showed that these flavonoids had little effect on nocturnal bladder capacity but reduced nighttime frequency and nocturnal polyuria index.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Saima Sabrina, Yuji Takeda, Tomoyuki Kato, Sei Naito, Hiromi Ito, Yuki Takai, Masaki Ushijima, Takafumi Narisawa, Hidenori Kanno, Toshihiko Sakurai, Shinichi Saitoh, Akemi Araki, Norihiko Tsuchiya, Hironobu Asao
Summary: The combination of immune checkpoint inhibition (ICI) therapy with other treatments can improve therapeutic outcomes. In this study, the expression of various myeloid-derived suppressor cells (MDSCs) markers, such as GPI-80, CD16, and LAP-1, were analyzed before and during ICI therapy in 51 patients with advanced renal cell carcinoma. It was found that elevated CD16 and LAP-1 expressions after treatment were associated with a poor response to ICI therapy, while higher GPI-80 expression in neutrophils before therapy was correlated with a complete response.
Article
Urology & Nephrology
Shingo Kimura, Hiromichi Katayama, Eiichiro Ohara, Hiroshi Aoki, Rie Shibuya, Hiroshi Naganuma, Shigeto Ishidoya, Akihiro Ito
Summary: The study aims to investigate the need for careful postoperative monitoring for prostate cancer after holmium laser enucleation of the prostate (HoLEP). The results suggest that HoLEP is associated with the risk of potential prostate cancer. Postoperative PSA should be carefully monitored even if not diagnosed with prostate cancer with HoLEP specimen.
INTERNATIONAL JOURNAL OF UROLOGY
(2023)
Article
Medicine, General & Internal
Daigo Chiba, Yoshihide Kawasaki, Atsushi Miyagi, Yuki Katsumata, Yohei Satake, Shuichi Shimada, Hiromichi Katayama, Naoki Kawamorita, Shinichi Yamashita, Koji Mitsuzuka, Kanae Akita, Mika Watanabe, Akihiro Ito
Summary: This case study describes a 74-year-old male patient with left renal cancer lymph node metastasis and idiopathic multicentric Castleman disease (CD). The patient died due to uncontrollable renal cancer and poor improvement in the inflammatory response. It is important to exclude malignant tumors in the treatment of idiopathic multicentric CD.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
(2022)
Article
Oncology
Yoichiro Tohi, Takuma Kato, Jimpei Miyakawa, Ryuji Matsumoto, Hiroshi Sasaki, Koji Mitsuzuka, Junichi Inokuchi, Masafumi Matsumura, Akira Yokomizo, Hidefumi Kinoshita, Isao Hara, Norihiko Kawamura, Kohei Hashimoto, Masaharu Inoue, Jun Teishima, Hidenori Kanno, Hiroshi Fukuhara, Satoru Maruyama, Shinichi Sakamoto, Toshihiro Saito, Yoshiyuki Kakehi, Mikio Sugimoto
Summary: Adherence to criteria was not associated with unfavorable pathology in patients who opt for active surveillance and undergo radical prostatectomy. There was no significant difference in pathological findings and prostate-specific antigen recurrence-free survival between the off-criteria and on-criteria groups.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2022)